NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$329.83▼$329.8350-Day Range$313.97▼$329.8352-Week Range$158.38▼$329.99Volume5 shsAverage Volume832,048 shsMarket Capitalization$12.58 billionP/E RatioN/ADividend YieldN/APrice Target$293.92 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Karuna Therapeutics alerts: Email Address Karuna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside10.9% Downside$293.92 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.96) to ($7.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.05 out of 5 starsMedical Sector932nd out of 936 stocksPharmaceutical Preparations Industry435th out of 436 stocks 1.2 Analyst's Opinion Consensus RatingKaruna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageKaruna Therapeutics has received no research coverage in the past 90 days.Read more about Karuna Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KRTX. Previous Next 0.0 Dividend Strength Dividend YieldKaruna Therapeutics does not currently pay a dividend.Dividend GrowthKaruna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRTX. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karuna Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Karuna Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.96) to ($7.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaruna Therapeutics has a P/B Ratio of 9.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Karuna Therapeutics Stock (NASDAQ:KRTX)Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here KRTX Stock News HeadlinesApril 26, 2024 | investing.comS&P 500 Q1 earnings estimated growth improves; stocks up for weekApril 25, 2024 | investing.comBristol Myers posts quarterly loss, lays out $1.5 billion cost-saving planJuly 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.April 22, 2024 | bizjournals.comAfter Karuna's acquisition, former CEO lands new gig at Cambridge biotechApril 9, 2024 | msn.comSeaport Therapeutics has $100 million to develop new ways to treat mental disordersMarch 15, 2024 | finance.yahoo.comLoss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-TermMarch 15, 2024 | ca.finance.yahoo.comKRTX May 2024 210.000 callMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)July 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.March 4, 2024 | finance.yahoo.comBronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short PositionFebruary 26, 2024 | msn.comKaruna Therapeutics drops on no apparent news amid deal with Bristol-Myers SquibbFebruary 23, 2024 | benzinga.com1KRTX : Karuna Therapeutics: Q4 Earnings InsightsFebruary 22, 2024 | msn.comKaruna Therapeutics GAAP EPS of -$3.01 misses by $0.29February 22, 2024 | finance.yahoo.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 22, 2024 | businesswire.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 21, 2024 | seekingalpha.comBronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of ProcessFebruary 18, 2024 | seekingalpha.comKaruna Therapeutics: Getting Sold ShortFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 320.000 callSee More Headlines Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees339Year FoundedN/APrice Target and Rating Average Stock Price Target$293.92 High Stock Price Target$330.00 Low Stock Price Target$225.00 Potential Upside/Downside-10.9%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($11.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-433,680,000.00 Net MarginsN/A Pretax Margin-66,209.48% Return on Equity-31.63% Return on Assets-30.38% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$654,000.00 Price / Sales19,239.07 Cash FlowN/A Price / Cash FlowN/A Book Value$33.24 per share Price / Book9.92Miscellaneous Outstanding Shares38,148,000Free Float33,157,000Market Cap$12.58 billion OptionableOptionable Beta1.18 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Andrew Craig Miller Ph.D. (Age 42)Founder and President of Research & Development Comp: $835.4kDr. Stephen K. Brannan (Age 68)Chief Medical Officer Comp: $751.75kMr. William Meury (Age 56)President, CEO & Director Mr. Jason Parker BrownChief Financial OfficerMs. Alexis SmithVice President of Corporate Affairs & Investor RelationsMs. Mia Kelley J.D.General CounselMr. Frank TruslowSenior Vice President of Corporate DevelopmentMr. Jonathan RosinChief Human Resources OfficerDr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorDr. Ronald N. Marcus M.D. (Age 66)Senior Vice President of Medical More ExecutivesKey CompetitorsGlobal Blood TherapeuticsNASDAQ:GBTTaro Pharmaceutical IndustriesNYSE:TAROOPKO HealthNASDAQ:OPKADC TherapeuticsNYSE:ADCTTakeda PharmaceuticalNYSE:TAKView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 1,100 shares on 5/17/2024Ownership: 0.000%PEAK6 Investments LLCSold 4,000 shares on 5/15/2024Ownership: 0.000%Stephen K BrannanSold 5,000 sharesTotal: $1.59 M ($318.34/share)Stephen K BrannanSold 5,000 sharesTotal: $1.58 M ($316.13/share)Stephen K BrannanSold 15,000 sharesTotal: $4.75 M ($316.81/share)View All Insider TransactionsView All Institutional Transactions KRTX Stock Analysis - Frequently Asked Questions How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) announced its earnings results on Thursday, February, 22nd. The company reported ($3.01) earnings per share for the quarter, missing the consensus estimate of ($2.65) by $0.36. The firm's revenue for the quarter was down 100.0% compared to the same quarter last year. When did Karuna Therapeutics IPO? Karuna Therapeutics (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA) and Johnson & Johnson (JNJ). This page (NASDAQ:KRTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karuna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KRTX Stock Alerts